Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
NCT02844439
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Glioblastoma
Recurrent Glioblastoma
Brain Tumor
Interventions
DRUG:
Tesevatinib
Sponsor
Kadmon Corporation, LLC